MIRA Pharmaceuticals, Inc. (MIRA) — Financial statements
Income statement, balance sheet, and cash flow for MIRA Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 2↓48.0% | 3↑110.1% | 2↓33.1% | 2↑243.6% | 0.68 | |
| General & Administrative Expenses | 9↑86.2% | 5↓27.5% | 6↑117.2% | 3↑288.5% | 0.77 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 9↑86.2% | 5↓27.5% | 6↑117.2% | 3↑288.5% | 0.77 | |
| Other Expenses | 0.00 | 0.00↓100.0% | 0.45↓73.4% | 2↑144.3% | 0.70 | |
| Operating Expenses | 10↑30.9% | 8↓6.0% | 9↑21.0% | 7↑227.5% | 2 | |
| Total Costs & Expenses | 10↑30.9% | 8↓6.0% | 9↑21.0% | 7↑227.5% | 2 | |
| Operating Results | ||||||
| Operating Income | -10↓30.9% | -8↑6.0% | -9↓21.0% | -7↓227.5% | -2 | |
| Depreciation & Amortization | 0.00↑100.0% | -0.00 | 0.00↓100.0% | 7↑227.5% | 2 | |
| EBITDA | -10↓30.9% | -8↑6.0% | -9 | 0.00 | 0.00 | |
| EBIT | -10↓30.9% | -8↑6.0% | -9↓21.0% | -7↓227.5% | -2 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.10↑159.7% | -0.17↑95.2% | -3↓33619.9% | -0.01↑57.9% | -0.02 | |
| Interest Income | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00↓100.0% | 0.17↓95.2% | 3↑33619.9% | 0.01↓57.9% | 0.02 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.05↓69.4% | 0.17↑104.8% | -3↓33619.9% | -0.01↑57.9% | -0.02 | |
| Income Before Tax | -10↓33.0% | -8↑34.5% | -12↓69.8% | -7↓224.3% | -2 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -10↓33.0% | -8↑34.5% | -12↓69.8% | -7↓224.3% | -2 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -10↓33.0% | -8↑34.5% | -12↓69.8% | -7↓224.3% | -2 | |
| Bottom-Line Net Income | -32↓307.5% | -8↑34.5% | -12↓69.8% | -7↓224.3% | -2 | |
| EPS (Basic) | -1.35↓164.7% | -0.51↑21.5% | -0.65↓35.4% | -0.48↓220.0% | -0.15 | |
| EPS (Diluted) | -1.35↓164.7% | -0.51↑21.5% | -0.65↓35.4% | -0.48↓220.0% | -0.15 | |
| Weighted Average Shares | 24↑53.4% | 15↓16.8% | 19↑25.9% | 15↑0.0% | 15 | |
| Weighted Average Diluted Shares | 24↑53.4% | 15↓16.8% | 19↑25.9% | 15↑0.0% | 15 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.